Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Fitzgerald

Showing results (581-590 of 629) with videos related to

Pageof 63
Sort By:
The European Respiratory Journal|July 25, 2015
A summary of the new GINA strategy: a roadmap to asthma controlHelen K Reddel, Eric D Bateman, Allan Becker, et al.
The European Respiratory Journal|November 3, 2022
Patient and physician factors associated with symptomatic undiagnosed asthma or COPDMathew Cherian, Kate M A Magner, G A Whitmore, et al.
The European Respiratory Journal|October 20, 2021
Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changesHelen K Reddel, Leonard B Bacharier, Eric D Bateman, et al.
Respirology (Carlton, Vic.)|October 20, 2021
Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key ChangesHelen K Reddel, Leonard B Bacharier, Eric D Bateman, et al.
Archivos De Bronconeumologia|March 4, 2022
Global Initiative for Asthma Strategy 2021. Executive Summary and Rationale for Key ChangesHelen K Reddel, Leonard B Bacharier, Eric D Bateman, et al.
The Journal of Infection|March 2, 2024
Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomesGail Hayward, Ly-Mee Yu, Paul Little, et al.
The Journal of Allergy and Clinical Immunology|May 18, 2016
Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responsesGail M Gauvreau, Jonathan P Arm, Louis-Philippe Boulet, et al.
The New England Journal of Medicine|May 22, 2018
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled AsthmaMario Castro, Jonathan Corren, Ian D Pavord, et al.
The Journal of Infection|August 31, 2024
Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomesFd Richard Hobbs, Oghenekome A Gbinigie-Thompson, Milensu Shanyinde, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 14, 2020
Potential Severe Asthma Hidden in UK Primary CareDermot Ryan, Heath Heatley, Liam G Heaney, et al.
Pageof 63

Showing results (581-590 of 629) with videos related to

Sort By:
Pageof 63
The European Respiratory Journal|July 25, 2015
A summary of the new GINA strategy: a roadmap to asthma controlHelen K Reddel, Eric D Bateman, Allan Becker, et al.
The European Respiratory Journal|November 3, 2022
Patient and physician factors associated with symptomatic undiagnosed asthma or COPDMathew Cherian, Kate M A Magner, G A Whitmore, et al.
The European Respiratory Journal|October 20, 2021
Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changesHelen K Reddel, Leonard B Bacharier, Eric D Bateman, et al.
Respirology (Carlton, Vic.)|October 20, 2021
Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key ChangesHelen K Reddel, Leonard B Bacharier, Eric D Bateman, et al.
Archivos De Bronconeumologia|March 4, 2022
Global Initiative for Asthma Strategy 2021. Executive Summary and Rationale for Key ChangesHelen K Reddel, Leonard B Bacharier, Eric D Bateman, et al.
The Journal of Infection|March 2, 2024
Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomesGail Hayward, Ly-Mee Yu, Paul Little, et al.
The Journal of Allergy and Clinical Immunology|May 18, 2016
Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responsesGail M Gauvreau, Jonathan P Arm, Louis-Philippe Boulet, et al.
The New England Journal of Medicine|May 22, 2018
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled AsthmaMario Castro, Jonathan Corren, Ian D Pavord, et al.
The Journal of Infection|August 31, 2024
Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomesFd Richard Hobbs, Oghenekome A Gbinigie-Thompson, Milensu Shanyinde, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 14, 2020
Potential Severe Asthma Hidden in UK Primary CareDermot Ryan, Heath Heatley, Liam G Heaney, et al.
Pageof 63